Today: 7 February 2026
Subscribe
Browse Category

Healthcare Industry News 3 December 2025 - 12 December 2025

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 (+1.80%) and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2 Note on timing: Saturday, Dec. 13, 2025 is a weekend, so U.S. stock markets
12 December 2025
·····
CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

Published: December 12, 2025 CSL Limited stock (ASX: CSL) is back in the spotlight on December 12, 2025, with fresh disclosure showing the company’s on-market share buyback is still running at pace—while investors continue weighing a messy mix of catalysts: vaccine-market volatility, government scrutiny of Australia’s “sovereign manufacturing” deals, and a pipeline story that just landed in The New England Journal of Medicine. As of today, Investing.com shows CSL trading around A$182.42, versus a previous close of A$178.81, with an intraday range of A$179.45–A$182.72 and a 52-week range of A$168.00–A$290.32. Investing.com Below is a detailed wrap of the most relevant
12 December 2025
·····
GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing, and a cluster of U.S. FDA decisions is about to test how much of that optimism is justified. As of last night’s close, GSK’s U.S. ADR finished at $48.40, up more than 45% year‑to‑date, while the London‑listed shares recently changed hands around 1,800p, having pushed above their 200‑day moving average of 1,547.73p on heavy volume. MarketBeat+1 Below is a deep
11 December 2025
·····
UnitedHealth Group (UNH) Stock Forecast 2026: Can the Healthcare Giant Recover From 2025’s Crises?

UnitedHealth Group (UNH) Stock Forecast 2026: Can the Healthcare Giant Recover From 2025’s Crises?

Published: December 10, 2025 – All data current as of market close on this date. This article is for informational purposes only and is not investment advice. UnitedHealth Group stock today: A blue chip in the penalty box UnitedHealth Group Incorporated (NYSE: UNH) – long considered one of the steadiest blue chips in U.S. healthcare – is ending 2025 in unfamiliar territory. That’s a jarring reversal for a company that, until recently, was famed for its consistent earnings growth, rising dividend, and defensive profile. Yet underneath the share-price pain, UnitedHealth’s business is still growing. Total revenue in the first nine
10 December 2025
····
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda and the broader pipeline. As of late trading on December 10, 2025, Merck stock changes hands around $97.27, up slightly on the day after yesterday’s pullback. MarketWatch+1 Over roughly the past month, shares have climbed about 20%, helped by positive trial results and optimism around newer products like Winrevair. Finviz This article walks through the latest news from December 10,
10 December 2025
·····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no wrong” growth icon to a complex mix of structural strengths (dominant GLP‑1 franchise, deep pipeline, global reach) and cyclical headaches (pricing pressure, competition, R&D setbacks). The Alzheimer’s shock: EVOKE and EVOKE+ miss their goal The biggest single blow of 2025
7 December 2025
·····
Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

As of the close on 5 December 2025, Medtronic plc (NYSE: MDT) stock trades around $101.36–$101.39 per share, giving the medical device giant a market capitalization of roughly $130 billion, a P/E ratio near 27.4, and a dividend yield of about 2.8%. MarketBeat+2StockAnalysis+2 In the first week of December, Medtronic has delivered a flurry of stock‑moving news: a new FDA clearance for its Hugo™ robotic-assisted surgery system, a U.S. launch of its next‑gen MiniMed™ 780G insulin pump with Abbott’s Instinct™ sensor, a fresh quarterly dividend declaration, and ongoing progress toward the spin‑off of its Diabetes business. At the same time,
6 December 2025
·····
UnitedHealth Group (UNH) Stock on December 5, 2025: Recovery Rally, 2026 Forecasts and the Legal Risks Investors Can’t Ignore

UnitedHealth Group (UNH) Stock on December 5, 2025: Recovery Rally, 2026 Forecasts and the Legal Risks Investors Can’t Ignore

UnitedHealth Group Incorporated (NYSE: UNH) is back in focus after a bruising year that saw the stock plunge to a five‑year low, attract a U.S. Department of Justice investigation, suffer the largest healthcare data breach in U.S. history – and then stage a powerful recovery rally into late 2025. As of the latest quote on December 5, 2025, UNH trades around $332–$334 per share, down modestly on the day but still well above its May lows near the mid‑$230s.MarketBeat The stock remains roughly 45% below its late‑2024 high near $610, underscoring how much damage has been done – and how
5 December 2025
···
CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

Updated: 4 December 2025 CSL Limited (ASX:CSL), the Australian biotech heavyweight, is trading around A$183 per share on 4 December 2025 after one of the most bruising years in its modern history. The company has delivered solid profit growth, announced thousands of job cuts, delayed a major spin‑off, launched a A$750 million buy‑back and opened a A$1 billion cell‑based vaccine and antivenom plant in Melbourne – all while its share price has fallen by roughly a third. Intelligent Investor+2Global Newsroom | CSL+2 Against that backdrop, investors are trying to decide whether CSL is now a long‑term bargain or a restructuring
4 December 2025
····
McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (NYSE: MCK) is ending 2025 as one of the standout performers in U.S. healthcare — but as of Wednesday, December 3, its stock is taking a breather. At the close, McKesson shares finished at $805.37, down 2.93% on the day and roughly 10% below their recent 52‑week high near $895, even after a powerful rally through most of the year.Wallstrank+2MarketWatch+2 Behind that pullback is a mix of profit‑taking after record highs, institutional portfolio shuffling, and investors digesting a wave of new guidance, long‑term targets, oncology initiatives and valuation debates. This article walks through: Key Takeaways on McKesson Stock
4 December 2025
····
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

As of December 2, 2025, CVS Health Corporation (NYSE: CVS) finds itself in a classic “good news, bad headlines” moment: the stock has pulled back after a strong 2025 rally, the company agreed to a federal settlement over insulin-pen billing, and yet Wall Street’s forecasts still point to further upside. Below is a structured rundown of the latest price action, news, forecasts and analyses as of and since December 2, 2025. Share price on December 2, 2025: dip after a big year On Tuesday, December 2, 2025, CVS Health shares fell about 1.9%, closing at $77.62, even as the broader
3 December 2025
·····
HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare, Inc. (NYSE:HCA) is ending 2025 on a powerful note. After a year of double‑digit earnings growth and upgraded guidance, HCA stock is trading just above $500 per share, close to its 52‑week high of $520 and implying a market capitalization around $117 billion. MarketBeat On November 25, the stock touched an all‑time high of $515.85, and as of December 2 it was still near $503, more than 38% above its July 2024 peak of $363.05 — a rally powered by strong results from the company’s 191‑hospital network and an aggressive capital program. Becker’s Hospital Review This article rounds
3 December 2025
···
1 … 7 8 9 10 11 12

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop